InvestSMART

De.mem Limited (ASX:DEM)

ALERT: Price-sensitive ASX Announcement for DEM
Current share price for DEM : $0.098 -0.002 (-2%)+
Announcement
Release
27 Feb 2026 11:36AM
Price at Release
$0.100
Full Release
download
Summary
De.mem Limited, in its 2025 Annual Report and Appendix 4E, reported a substantial net loss and highlighted significant progress with its Felix™ System, aimed at improving assisted reproductive technology procedures. The company successfully completed a crucial Phase III clinical trial, showing the Felix™ System's superiority and safety, and moved towards regulatory approval by submitting a CE Mark application. De.mem Limited is focusing on commercializing the Felix™ System with strategic direct sales initiatives in less regulated markets, despite a dramatic decrease in revenue from continuing operations.
Key Points
  • De.mem Limited reported a net loss of $4.94 million for the financial year ending 30 June 2025.
  • The company achieved a critical milestone with the successful delivery of a pivotal Phase III clinical trial for the Felix™ System in collaboration with Monash IVF.
  • The Felix™ System demonstrated superiority in embryo utilisation rate and received a strong preference from embryologists.
  • De.mem Limited submitted its CE Mark regulatory dossier for the Felix™ System in June 2025.
  • Strategic advice suggests the CE Mark registration could take 6-12 months.
  • The company is prioritizing direct sales of its Felix™ System, targeting early market deployment in countries with minimal regulatory requirements.
  • Revenue from continuing ordinary activities decreased by 94% compared to the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.